Clover Biopharmaceuticals AUS Pty
16
1
1
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
43.8%
7 terminated/withdrawn out of 16 trials
53.3%
-33.2% vs industry average
25%
4 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
Role: lead
First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
Role: lead
Safety and Immunogenicity Study of SCB-1019T in Children
Role: lead
Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults
Role: lead
Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults
Role: lead
Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults
Role: lead
Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults
Role: lead
A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19
Role: lead
Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases
Role: lead
Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age
Role: lead
Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration
Role: lead
SCB-2019 as COVID-19 Vaccine
Role: lead
Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.
Role: lead
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions
Role: lead
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies
Role: lead
Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults
Role: lead
All 16 trials loaded